Momenta Pharmaceuticals Inc (MNTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Momenta Pharmaceuticals Inc (MNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10018
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The company’s products include Glatopa; and Enoxaparin Sodium Injection. Its pipeline portfolio encompasses candidates to substitute Copaxone 40 mg/mL, Humira, and Orencia; an anti-FcRn antibody; selective immune-modulator of Fc receptors; hyper-sialylated IVIg as well as investigational candidate for the treatment of pancreatic cancer. The company utilizes its technology for developing generic versions of biosimilars, complex drugs, and potentially interchangeable biologics, and also in the discovery and development of therapeutics for various cancers and autoimmune indications. Momenta is headquartered in Cambridge, Massachusetts, the US.

Momenta Pharmaceuticals Inc (MNTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Partnerships 12
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
Licensing Agreements 13
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Equity Offering 19
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc – Key Competitors 23
Momenta Pharmaceuticals Inc – Key Employees 24
Momenta Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2018: Momenta Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 26
Aug 09, 2018: Momenta Pharmaceuticals announces second quarter 2018 financial results 28
May 08, 2018: Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 30
Feb 21, 2018: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 33
Nov 01, 2017: Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 02, 2017: Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 39
May 02, 2017: Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results 42
Feb 21, 2017: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 45
Corporate Communications 48
Oct 02, 2017: Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer 48
Jun 01, 2017: Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer 49
Legal and Regulatory 50
Mar 21, 2018: Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals and Sandoz 50
Government and Public Interest 51
Jan 06, 2017: Momenta Provides Year-End 2016 Corporate Update 51
Product News 53
05/17/2018: Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity 53
01/03/2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept) 54
Clinical Trials 55
Jan 05, 2018: Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc, Key Competitors 23
Momenta Pharmaceuticals Inc, Key Employees 24
Momenta Pharmaceuticals Inc, Subsidiaries 25

List of Figures
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Momenta Pharmaceuticals Inc (MNTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MTU Aero Engines Holdings AG (MTX):企業の財務・戦略的SWOT分析
    MTU Aero Engines Holdings AG (MTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Herman Miller, Inc.:企業の戦略・SWOT・財務分析
    Herman Miller, Inc. - Strategy, SWOT and Corporate Finance Report Summary Herman Miller, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Quadrise Fuels International Plc (QFI)-石油・ガス分野:企業M&A・提携分析
    Summary Quadrise Fuels International Plc (QFI), formerly Zareba Plc, is an oil-in-water emulsified fuel developer that manufactures and markets MSAR (Multiphase Superfine Atomised Residue), an emulsion fuel as a low cost substitute for conventional heavy fuel oil (HFO) for use in power generation pl …
  • WEG SA:戦略・SWOT・企業財務分析
    WEG SA - Strategy, SWOT and Corporate Finance Report Summary WEG SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Simons Group Ltd:企業の戦略・SWOT・財務情報
    Simons Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Simons Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Exxon Mobil Corp (XOM):電力:M&Aディール及び事業提携情報
    Summary Exxon Mobil Corp (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. It is a major manufacturer and …
  • TIE Kinetix NV (TIE):企業の財務・戦略的SWOT分析
    TIE Kinetix NV (TIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析
    Summary Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hy …
  • Energoprojekt Holding AD (ENHL):企業の財務・戦略的SWOT分析
    Energoprojekt Holding AD (ENHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Adimmune Corp (4142):製薬・医療:M&Aディール及び事業提携情報
    Summary Adimmune Corp (Adimmune) is a biopharmaceutical company that manufactures diagnostics, vaccines, and biological products for various diseases. The corporation’s products include tetanus toxoid adsorbed vaccine, influenza vaccine, Japan encephalitis vaccine, and ah1n1 vaccine. It also provide …
  • HOB Biotech Group Suzhou Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary HOB Biotech Group Suzhou Co Ltd (HOB Biotech) is a manufacturer of allergy and autoimmune in vitro diagnostics. It owns and operates bioclia, bioline, and biolisa. The company’s bioclia is engaged in cutting-edge nanoparticle and chemiluminescent technology, and chemiluminescent immuno assay …
  • Phillips 66 Co (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 Co (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hokkaido Electric Power Co Inc (9509):企業の財務・戦略的SWOT分析
    Hokkaido Electric Power Co Inc (9509) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Orexo AB (ORX):製薬・医療:M&Aディール及び事業提携情報
    Summary Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company's commercial product portfolio consists of Abstral, Edluar and Zubsolv. its pipeline candidates comprise OX51 for procedure- …
  • Northstar Electronics, Inc.:企業の戦略・SWOT・財務分析
    Northstar Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Northstar Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Taita Chemical Co, Ltd (1309):企業の財務・戦略的SWOT分析
    Taita Chemical Co, Ltd (1309) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Precision System Science Co Ltd (7707)-医療機器分野:企業M&A・提携分析
    Summary Precision System Science Co Ltd (PSS) is a medical device company that develops, manufactures and sells automated systems, physicochemical instruments, software, and others. The company’s products include automated nucleic acid isolation system, large sample volume nucleic acid extraction sy …
  • OCI Co Ltd (010060):電力:M&Aディール及び事業提携情報
    Summary OCI Co Ltd (OCI) is a green energy and chemical company. It manufactures and sells a wide range of inorganic chemicals, coal and petrochemicals, and fine chemicals. The company’s product portfolio includes toluene di-isocyanate (TDI), hydrogen peroxide, carbon black, pitch, sodium percarbona …
  • Dewan Housing Finance Corporation Limited:企業のM&A・事業提携・投資動向
    Dewan Housing Finance Corporation Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dewan Housing Finance Corporation Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detaile …
  • Apache Corporation:戦略・SWOT・企業財務分析
    Apache Corporation - Strategy, SWOT and Corporate Finance Report Summary Apache Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆